NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Pedro A Piedra · BAYLOR COLLEGE OF MEDICINE · 2021 · $352,938 — PROJECT SUMMARY – Project 2 Respiratory syncytial virus (RSV) is a major global respiratory pathogen. The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic has resulted in an unprecedented crisis. Respiratory virus infections are often accompanied by gastrointestinal (GI) symptom…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Vincent C Bond · MOREHOUSE SCHOOL OF MEDICINE · 2021 · $177,500 — Abstract: Diversity in the rates of progression and mortality of COVID-19 disease within infected African American (AAs) subgroups are clearly not just a function of the underlying health conditions that increase the rate of mortality for COVID -19 patients, such as hypertension, obesity and diabete…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Craig Andrew Miller · OKLAHOMA STATE UNIVERSITY STILLWATER · 2021 · $240,655 — The overall objective of this project is to validate mechanisms of viral fitness and immunopathogenesis during SARS-CoV-2 infection in domestic cats to establish baselines for downstream translational studies. Major goals (specific aims) for this project are as follows: Aim 1. Evaluate in vivo in…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
LINDA CHANG · UNIVERSITY OF MARYLAND BALTIMORE · 2021 · $424,875 — Project Summary This R21 Exploratory/Developmental Research Grant is written in response to PAR-20-177: Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). SARS-CoV2 is the virus that causes COVID-19, and is k…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Laurent Olivier Mosnier · SCRIPPS RESEARCH INSTITUTE, THE · 2021 · $443,750 — Project Summary This application seeks to improve basic understanding of the molecular mechanisms that mediate cytoprotective actions of coagulation proteases on cells and will test novel approaches for the potential treatment of thrombo- inflammatory disease. Despite recent advances, major gaps in …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Catalin Filipeanu · LSU HEALTH SCIENCES CENTER · 2021 · $600,541 — With prevalence as high as 55% for individuals aged 55 and older in United States, hypertension is a major risk factor contributing to cardiovascular diseases (CVD) and global mortality, hence remaining an increasingly important medical and public health issue. The role of the renin-angiotensin syst…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Noam A Cohen · PHILADELPHIA VA MEDICAL CENTER · 2021 — ABSTRACT Severe acute respiratory syndrome coronavirus SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19) has led to a pandemic with a mortality of approximately 3.5% and a wide range of morbidity outcomes negatively impacted by pre-existing conditions. Given the prevalence of p…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Yagna Jarajapu · NORTH DAKOTA STATE UNIVERSITY · 2021 · $253,750 — Targeting Mas Receptor for Diabetic Vascular Disease in Older Adults Abstract Prevalence of diabetes is high among older adults and is expected to rise, and diabetes increases risk for cardiovascular disease. Accumulated evidence suggests that bone marrow-derived progenitor cells maintain vascular h…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Florian Douam · BOSTON UNIVERSITY MEDICAL CAMPUS · 2021 · $242,950 — Project Summary We are in the midst of an unprecedented, modern pandemic as a result of the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019. SARS-CoV-2 is one of three known coronaviruses that can replicate in the lower respiratory tract and cause pneumoni…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
DAVID G BESSELSEN · UNIVERSITY OF ARIZONA · 2021 · $306,997 — ABSTRACT The pandemic COronaVIrus disease 2019 (COVID-19) is an infectious disease, which is caused by a novel and highly pathogenic virus strain SARS-CoV-2 (Severe acute respiratory virus syndrome coronavirus 2). The infection may cause severe lower respiratory tract infection with acute respirator…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
KATHLEEN E. RODGERS · UNIVERSITY OF ARIZONA · 2021 · $1,531,012 — PROJECT SUMMARY/ABSTRACT Alzheimer’s disease (AD) is a progressive multifactorial disease affecting more than 50 million people worldwide, and is the most common dementia of late-life. To date, no interventions have demonstrated substantial therapeutic efficacy to prevent, delay or treat AD. In rece…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Susan P Travers · OHIO STATE UNIVERSITY · 2021 · $305,085 — The goals of this Emergency Competitive Revision are to develop (Aim 1) and deploy (Aim 2) a novel, objective, psychophysical smell and taste screening test to detect the onset of COVID 19 in at-risk populations. Complementary to the temperature screening procedures currently in use, this tool is pr…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Yufen CHEN · NORTHWESTERN UNIVERSITY AT CHICAGO · 2021 · $439,694 — This investigation will use state-of-the-art, quantitative Magnetic Resonance Imaging to determine whether SARS-CoV-2 has effects on the brain that can be detected at one month and at 6 months following mild to moderate COVID. Blood brain barrier integrity, cerebral blood flow, cerebrovascular injur…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
RICHARD J SMEYNE · THOMAS JEFFERSON UNIVERSITY · 2021 · $429,000 — ABSTRACT Approximately16.5 million people have been infected with the SARS-CoV2 virus with approximately 650,000 (and rising) deaths. While primarily a respiratory virus, clinical observations appear to demonstrate nervous system involvement. These include those associated with the CNS (headache, c…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Qizhi Gong · UNIVERSITY OF CALIFORNIA AT DAVIS · 2021 · $235,500 — PROJECT SUMMARY A sudden onset of olfactory impairment is reported as one of the early clinical manifestations of COVID-19, particularly among mild and asymptomatic patients. Though reports indicate that olfactory loss resolves within two weeks, it is unknown what proportion of the patients develops…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Vaithilingaraja Arumugaswami · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2021 · $3,636,473 — Project Summary/Abstract SARS-CoV-2 primarily affects the respiratory system but extra-pulmonary manifestations in individuals with COVID-19 are commonly seen. All major organ systems have been reported to be affected by SARS-CoV-2 and complications arising from ensuing organ dysfunction significant…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Sumant Singh Chugh · RUSH UNIVERSITY MEDICAL CENTER · 2021 · $562,646 — Abstract The COVID 19 pandemic has been associated with the development of proteinuria in up to 40% of hospitalized patients. This cardinal manifestation of kidney disease is most likely related to effects of the extensive cytokine storm in these patients on glomeruli, the filtering units of the kid…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Matthew J. Flick · UNIV OF NORTH CAROLINA CHAPEL HILL · 2021 · $580,295 — SUMMARY Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2; CoV2) is the first highly pathogenic and highly transmissible human coronavirus that is the causative agent for the worldwide COVID-19 pandemic. As of November 2020, 50 million cases of CoV2 infection worldwide and 1.25 million dea…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Takako Araki · UNIVERSITY OF MINNESOTA · 2021 · $421,625 — PROJECT SUMMARY COVID-19–related extra-pulmonary damage is common and may even be observed in patients with mild COVID- 19 symptoms. There is an urgent and immediate need to establish optimal post-infection health care strategies for these patients, yet mechanisms underlying their appearance remain …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Cathleen M Lutz · JACKSON LABORATORY · 2021 · $491,863 — Abstract To date, most of the research using mouse models for COVID-19 has been done using a transgenic mouse model expressing high levels of the human ACE2gene driven by the Keratin-18(K18) promoter. While this model has been extremely useful, it has some notable limitations: disease progression is…